Comparative study on the immunogenicity between an HLA-A24-restricted cytotoxic T-cell epitope derived from survivin and that from its splice variant survivin-2B in oral cancer patients.
Comparative study on the immunogenicity between an HLA-A24-restricted cytotoxic T-cell epitope derived from survivin and that from its splice variant survivin-2B in oral cancer patients.
复制标题
DOI：
10.1186/1479-5876-7-1
复制
发表时间：
2009-01-06
影响因子：
7.4
通讯作者：
Sato N
中科院分区：
文献类型：
--
作者：
Kobayashi J;Torigoe T;Hirohashi Y;Idenoue S;Miyazaki A;Yamaguchi A;Hiratsuka H;Sato N
我们之前报道了hla - a24限制性细胞毒性t细胞表位survivin- 2b80 -88，来源于survivin- 2b的剪接变体。在本报告中，我们展示了一种新的hla - a24限制性t细胞表位，survivin - c58，来源于一种野生型survivin，并比较了它们在口腔癌患者中的免疫原性。体外用Survivin-C58肽刺激hla - a24阳性肿瘤患者外周血淋巴细胞，诱导肽特异性ctl。为了比较C58肽和2B80-88肽的免疫原性潜能，我们用13例hla - a24阳性口腔癌患者的外周血t细胞分别用这两种肽中的一种或两种刺激。4例患者诱导了Survivin-2B80-88肽特异性ctl， 8例II期以上进展患者中的3例诱导了C58肽特异性ctl。ctl对hla - a24阳性肿瘤细胞具有细胞毒性。相比之下，一名健康志愿者和所有四名i期癌症患者的CTL诱导失败。这表明，剪切变体衍生肽和野生型survivin衍生肽可能具有相当的CTL诱导能力，使用survivin- 2b80 -88和C58肽混合物的survivin靶向免疫治疗应该适用于HLA-A24+口腔癌患者。
We previously reported an HLA-A24-restricted cytotoxic T-cell epitope, Survivin-2B80-88, derived from a splice variant of survivin, survivin-2B. In this report, we show a novel HLA-A24-restricted T-cell epitope, Survivin-C58, derived from a wild type survivin, and compared their immunogenicity in oral cancer patients. By stimulating peripheral blood lymphocytes of HLA-A24-positive cancer patients with Survivin-C58 peptide in vitro, the peptide-specific CTLs were induced. In order to compare the immunogenic potential between C58 peptide and 2B80-88 peptide, peripheral blood T-cells from thirteen HLA-A24-positive oral cancer patients were stimulated with either or both of these two peptides. Survivin-2B80-88 peptide-specific CTLs were induced from four patients, and C58 peptide-specific CTLs were induced from three out of eight patients with over stage II progression. The CTLs exerted cytotoxicity against HLA-A24-positive tumor cells. In contrast, CTL induction failed from a healthy volunteer and all four patients with cancer stage I. It was indicated that a splicing variant-derived peptide and wild type survivin-derived peptide might have a comparable potency of CTL induction, and survivin targeting immunotherapy using survivin-2B80-88 and C58 peptide cocktail should be suitable for HLA-A24+ oral cancer patients.
登录
查看更多内容
影响因子：
11.5
作者：
Idenoue, S;Hirohashi, Y;Sato, N
通讯作者：
Sato, N
影响因子：
6.4
作者：
Rosato, Antonio;Pivetta, Michela;Zanovello, Paola
通讯作者：
Zanovello, Paola
影响因子：
11.2
作者：
Asanuma, H;Torigoe, T;Sato, N
通讯作者：
Sato, N
影响因子：
8
作者：
Caldas, H;Jiang, YY;Altura, RA
通讯作者：
Altura, RA
影响因子：
4.4
作者：
Sato, Y;Nabeta, Y;Sato, N
通讯作者：
Sato, N